ArticleJournal of neural transmission (Vienna, Austria : 1996)2025
A cross-language speech model for detection of Parkinson's disease.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Development and clinical translation of smartphone-based digital biomarkers for Parkinson's disease: a structured review.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Multimodal Intelligent Monitoring of Parkinson Disease: Scoping Review of Progress and Translational Challenges.Journal of medical Internet research · 2026Article
- ParkMAE: a cross-linguistic masked autoencoder framework for robust Parkinson's disease detection from speech.Scientific reports · 2025Article
- Voice-Based Detection of Parkinson's Disease Using Machine and Deep Learning Approaches: A Systematic Review.Bioengineering (Basel, Switzerland) · 2025Review
- Speech-Based Parkinson's Detection Using Pre-Trained Self-Supervised Automatic Speech Recognition (ASR) Models and Supervised Contrastive Learning.Bioengineering (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Speech change is a biometric marker for Parkinson's disease (PD). However, evaluating speech variability across diverse languages is challenging. We aimed to develop a cross-language algorithm differentiating between PD patients and healthy controls using a Taiwanese and Korean speech data set. We recruited 299 healthy controls and 347 patients with PD from Taiwan and Korea. Participants with PD underwent smartphone-based speech recordings during the "on" phase. Each Korean participant performed various speech texts, while the Taiwanese participant read a standardized, fixed-length article. Korean short-speech (≦15 syllables) and long-speech (> 15 syllables) recordings were combined with the Taiwanese speech dataset. The merged dataset was split into a training set (controls vs. early-stage PD) and a validation set (controls vs. advanced-stage PD) to evaluate the model's effectiveness in differentiating PD patients from controls across languages based on speech length. Numerous acoustic and linguistic speech features were extracted and combined with machine learning algorithms to distinguish PD patients from controls. The area under the receiver operating characteristic (AUROC) curve was calculated to assess diagnostic performance. Random forest and AdaBoost classifiers showed an AUROC 0.82 for distinguishing patients with early-stage PD from controls. In the validation cohort, the random forest algorithm maintained this value (0.90) for discriminating advanced-stage PD patients. The model showed superior performance in the combined language cohort (AUROC 0.90) than either the Korean (AUROC 0.87) or Taiwanese (AUROC 0.88) cohorts individually. However, with another merged speech data set of short-speech recordings < 25 characters, the diagnostic performance to identify early-stage PD patients from controls dropped to 0.72 and showed a further limited ability to discriminate advanced-stage patients. Leveraging multifaceted speech features, including both acoustic and linguistic characteristics, could aid in distinguishing PD patients from healthy individuals, even across different languages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.